Benitec Biopharma Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Benitec Biopharma Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $123.00K, a 90.08% decline year-over-year.
- Benitec Biopharma Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $1.24M, a 3079.49% increase year-over-year.
- Benitec Biopharma Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $1.66M.
- Benitec Biopharma Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $39.00K.
- Benitec Biopharma Inc. stock issued during period, value, stock options exercised for fiscal 2026 was $123.00K, a 95.90% decline from fiscal 2025.
- Benitec Biopharma Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $3.00M, a 1478.42% increase from fiscal 2024.
- Benitec Biopharma Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $190.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $123.00K 10-K · filed 2026-09-14 | |
| 2025-12-31 | $123.00K 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $3.00M 10-K · filed 2026-09-14 | |
| 2024-12-31 | $1.24M 10-Q · filed 2026-05-14 | |
| 2024-09-30 | $1.66M 10-Q · filed 2026-05-14 | |
| 2024-06-30 | $190.00K 10-K/A · filed 2026-03-20 | |
| 2023-12-31 | $39.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |